B cell-targeted therapy with anti-CD20 monoclonal antibody in a mouse model of Graves' hyperthyroidism

Clinical and Experimental Immunology

Volumn 163, Issue 3, 2011, Pages 309-317

  Ueki, I ^a,b   Abiru, N ^b   Kobayashi, M ^b   Nakahara, M ^a   Ichikawa, T ^c   Eguchi, K ^b,c   Nagayama, Y ^a  

^a NAGASAKI UNIVERSITY   (Japan)

^b Divisions of Immunology   (Japan)

^c NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

Author keywords

Autoimmunity; B cells; Graves' disease

Indexed keywords

CD20 ANTIBODY; GAMMA INTERFERON; IMMUNOGLOBULIN G; THYROTROPIN RECEPTOR; THYROTROPIN RECEPTOR ANTIBODY;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCING CELL; ANTIBODY PRODUCTION; ANTIGEN PRESENTING CELL; ARTICLE; B LYMPHOCYTE; CYTOKINE RELEASE; DISEASE COURSE; DRUG EFFICACY; FEMALE; GRAVES DISEASE; IMMUNIZATION; IMMUNOGLOBULIN BLOOD LEVEL; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PERITONEUM; PRIORITY JOURNAL; SPLEEN; SPLEEN CELL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; B-LYMPHOCYTES; CELL COUNT; DISEASE MODELS, ANIMAL; FEMALE; GRAVES DISEASE; IMMUNOGLOBULIN G; IMMUNOGLOBULINS, THYROID-STIMULATING; INTERFERON-GAMMA; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; LYMPHOCYTE DEPLETION; MICE; MICE, INBRED BALB C; PERITONEAL CAVITY; RECEPTORS, THYROTROPIN; SPLEEN; T-LYMPHOCYTES; THYROXINE; VACCINES, DNA;

EID: 79551703436     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2010.04301.x     Document Type: Article

References (40)

1. Rapoport B, Chazenbalk GD, Jaume JC, McLachlan SM. The thyrotropin (TSH) receptor: interaction with TSH and autoantibodies. Endocr Rev 1998; 19:673-716.
2. Yanaba K, Bouaziz JD, Matsushita T, Magro CM, William St. Clair E, Tedder TF. B-lymphocyte contributions to human autoimmune disease. Immunol Rev 2008; 223:284-99.
3. Braley-Mullen H, Yu S. Early requirement for B cells for development of spontaneous autoimmune thyroiditis in NOD.H-2h4 mice. J Immunol 2000; 165:7262-69.
4. Shlomchik MJ, Madaio MP, Ni D, Trounstein M, Huszar D. The role of B cells in lpr/lpr-induced autoimmunity. J Exp Med 1994; 180:1295-306.
5. Serreze DV, Chapman HD, Varnum DS etal. B lymphocytes are essential for the initiation of T cell-mediated autoimmune diabetes: analysis of a new 'speed congenic' stock of NOD.Ig mu null mice. J Exp Med 1996; 184:2049-53.
6. Pichurin P, Aliesky H, Chen C-R, Nagayama Y, Rapoport B, McLachlan SM. Thyrotropin receptor-specific memory T cell responses require normal B cells in a murine model of Graves' disease. Clin Exp Immunol 2003; 134:396-402.
7. Chiu PP, Serreze DV, Danska JS. Development and function of diabetogenic T-cells in B-cell-deficient nonobese diabetic mice. Diabetes 2001; 50:763-70.
8. + T cell activation in mice. Proc Natl Acad Sci USA 2007; 104:20878-83.
9. Li Y, Chen F, Putt M etal. B cell depletion with Anti-CD79 mAbs ameliorates autoimmune disease in MRL/lpr mice. J Immunol 2008; 181:2961-72.
10. Zekavat G, Rostami SY, Badkerhanian A etal. In vivo BLyS/BAFF neutralization ameliorates islet-directed autoimmunity in nonobese diabetic mice. J Immunol 2008; 181:8133-44.
11. Uchida J, Hamaguchi Y, Oliver JA etal. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med 2004; 199:1659-69.
12. Sanz I, Anolik JH, Looney RJ. B cell depletion therapy in autoimmune diseases. Front Biosci 2007; 12:2546-67.
13. El Fassi D, Nielsen CH, Bonnema SJ, Hasselbalch HC, Hegedus L. B lymphocyte depletion with the monoclonal antibody rituximab in Graves' disease: a controlled pilot study. J Clin Endocrinol Metab 2007; 92:1769-72.
14. Salvi M, Vannucchi G, Campi I etal. Rituximab treatment in a patient with severe thyroid-associated ophthalmopathy: effects on orbital lymphocytic infiltrates. Clin Immunol 2009; 131:360-5.
15. Salvi M, Vannucchi G, Campi I etal. Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study. Eur J Endocrinol 2007; 156:33-40.
16. Heemstra KA, Toes RE, Sepers J etal. Rituximab in relapsing Graves' disease, a phase II study. Eur J Endocrinol 2008; 159:609-15.
17. Ahuja A, Shupe J, Dunn R, Kashgarian M, Kehry MR, Mark J. Shlomchik MJ. Depletion of B cells in murine lupus: efficacy and resistance. J Immunol 2007; 179:3351-61.
18. Yu S, Dunn R, Kehry MR, Braley-Mullen H. B cell depletion inhibits spontaneous autoimmune thyroiditis in NOD.H2-h4 mice. J Immunol 2008; 180:7706-13.
19. Yanaba K, Hamaguchi Y, Venturi GM, Steeber DA, William St Clair E, Tedder TF. B cell depletion delays collagen-induced arthritis in mice: arthritis induction requires synergy between humoral and cell-mediated immunity. J Immunol 2007; 179:1369-80.
20. Hasegawa M, Hamaguch Y, Yanaba K etal. B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis. Am J Pathol 2006; 169:954-66.
21. Hayakawa I, Tedder TF, Zhuang Y. B-lymphocyte depletion ameliorates Sjögren's syndrome in Id3 knockout mice. Immunology 2007; 122:73-9.
22. Xiu Y, Wong CP, Bouaziz JD etal. B lymphocyte depletion by CD20 monoclonal antibody prevents diabetes in nonobese diabetic mice despite isotype-specific differences in FcγR effector functions. J Immunol 2008; 180:2863-75.
23. Chen C-R, Pichurin P, Nagayama Y, Latrofa F, Rapoport B, McLachlan SM. The thyrotropin receptor autoantigen in Graves' disease is the culprit as well as the victim. J Clin Invest 2003; 111:1897-904.
24. + T cells, newly identified regulatory T cells, negatively regulate Graves' disease in a murine model. Endocrinology 2007; 148:6040-6.
25. Hamaguchi Y, Uchida J, Cain DW etal. The peritoneal cavity provides a protective niche for B1 and conventional B lymphocytes during anti-CD20 immunotherapy in mice. J Immunol 2005; 174:4389-99.
26. Nagayama Y, Mizuguchi H, Hayakawa T, Niwa M, McLachlan SM, Rapoport B. Prevention of autoantibody-mediated Graves'-like hyperthyroidism in mice by IL-4, a Th2 cytokine. J Immunol 2003; 170:3522-7.
27. Nagayama Y, Saitoh O, McLachlan SM, Rapoport B, Kano H, Kumazawa Y. TSH receptor-adenovirus-induced Graves' disease is attenuated in both interferon-γ and interleukin-4 knockout mice; implications for the Th1/Th2 paradigm. Clin Exp Immunol 2004; 138:417-22.
28. Hu CY, Rodriguez-Pinto D, Du W etal. Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice. J Clin Invest 2007; 117:3857-67.
29. Fiorina P, Vergani A, Dara S etal. Targeting CD22 reprograms B-cells and reversed autoimmune diabetes. Diabetes 2008; 57:3013-24.
30. Gilbert JA, Kalled SL, Moorhead J etal. Treatment of autoimmune hyperthyroidism in a murine model of Graves' disease with tumor necrosis factor-family ligand inhibitors suggests a key role for B cell activating factor in disease pathology. Endocrinology 2006; 147:4561-8.
31. Yan J, Harvey BP, Gee RJ, Shlomchik MJ, Mamula MJ. B cells drive early T cell autoimmunity in vivo prior to dendritic cell-mediated autoantigen presentation. J Immunol 2006; 177:4481-7.
32. Vallerskog T, Gunnarsson I, Widhe M etal. Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE. Clin Immunol 2006; 122:62-74.
33. Stasi R, Stipa E, Del Poeta G, Amadori S, Newland AC, Provan D. Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab. Rheumatology (Oxf) 2006; 45:1432-6.
34. Stasi R, Poeta GD, Stipa E etal. Response to B-cell-depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura. Blood 2007; 110:2924-30.
35. El Fassi D, Banga JP, Bilbert JA, Padoa C, Hegedus L, Nielsen CH. Treatment of Graves' disease with rituximab specifically reduces the production of thyroid stimulating autoantibodies. Clin Immunol 2009; 130:252-8.
36. Ferraro AJ, Drayson MT, Savage COS, MacLennan ICM. Levels of autoantibodies, unlike antibodies to all extrinsic antigen groups, fall following B cell depletion with Rituximab. Eur J Immunol 2008; 38:292-8.
37. Teng YK, Levarht EW, Hashemi M etal. Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment. Arthritis Rheum 2007; 56:3909-18.
38. Thurlings RM, Vos K, Wijbrandts CA, Zwinderman AH, Gerlag DM, Tak PP. Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response. Ann Rheum Dis 2008; 67:917-25.
39. Looney RJ, Anolik JH, Campbell D etal. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004; 50:2580-89.
40. Joly P, Mouquet H, Roujeau JC etal. A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med 2007; 357:545-52.